HTG Molecular Diagnostics Executives

HTGMDelisted Stock  USD 0.35  0.01  2.94%   
HTG Molecular employs about 53 people. The company is managed by 19 executives with a total tenure of roughly 127 years, averaging almost 6.0 years of service per executive, having 2.79 employees per reported executive. Analysis of HTG Molecular's management performance can provide insight into the firm performance.
Timothy Johnson  CEO
CEO and President and Director
Peter Bisgaard  Chairman
Independent Chairman of the Board
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

HTG Molecular Management Team Effectiveness

The company has return on total asset (ROA) of (0.6226) % which means that it has lost $0.6226 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4321) %, meaning that it created substantial loss on money invested by shareholders. HTG Molecular's management efficiency ratios could be used to measure how well HTG Molecular manages its routine affairs as well as how well it operates its assets and liabilities.

HTG Molecular Workforce Comparison

HTG Molecular Diagnostics is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 1,641. HTG Molecular holds roughly 53.0 in number of employees claiming about 3% of equities under Health Care industry.

HTG Molecular Notable Stakeholders

A HTG Molecular stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as HTG Molecular often face trade-offs trying to please all of them. HTG Molecular's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting HTG Molecular's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Timothy JohnsonCEO and President and DirectorProfile
Peter BisgaardIndependent Chairman of the BoardProfile
Maureen CroninSenior Vice President Chief Scientific OfficerProfile
Patrick RocheSenior Vice President - Research and Product DevelopmentProfile
Suzanne HillVice President of North American Capital SalesProfile
Debra GordonVice President and Chief Legal CounselProfile
Shaun McMeansCFO and VP of Fin. and Admin.Profile
Ann HanhamDirectorProfile
Lewis ShusterIndependent DirectorProfile
James LaFranceDirectorProfile
Lee McCrackenDirectorProfile
Michelle GriffinDirectorProfile
Harry GeorgeIndependent DirectorProfile
Mary HoultIndependent DirectorProfile
Donnie HardisonDirectorProfile
Laura GodlewskiPrincipal Accounting OfficerProfile
John LubniewskiChief Bus. OfficerProfile
Stephen BaratVP TherapeuticsProfile
Byron LawsonVP OfficerProfile

About HTG Molecular Management Performance

The success or failure of an entity such as HTG Molecular Diagnostics often depends on how effective the management is. HTG Molecular management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of HTG management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the HTG management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. Htg Molecular operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.
The data published in HTG Molecular's official financial statements usually reflect HTG Molecular's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of HTG Molecular Diagnostics. For example, before you start analyzing numbers published by HTG accountants, it's critical to develop an understanding of what HTG Molecular's liquidity, profitability, and earnings quality are in the context of the Health Care Technology space in which it operates.
Please note, the presentation of HTG Molecular's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HTG Molecular's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in HTG Molecular's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of HTG Molecular Diagnostics. Please utilize our Beneish M Score to check the likelihood of HTG Molecular's management manipulating its earnings.

HTG Molecular Workforce Analysis

Traditionally, organizations such as HTG Molecular use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare HTG Molecular within its industry.

HTG Molecular Manpower Efficiency

Return on HTG Molecular Manpower

Revenue Per Employee120.1K
Revenue Per Executive335.1K
Net Loss Per Employee407.4K
Net Loss Per Executive1.1M
Working Capital Per Employee139.3K
Working Capital Per Executive388.5K
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the HTG Molecular Diagnostics information on this page should be used as a complementary analysis to other HTG Molecular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in HTG Stock

If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Global Correlations
Find global opportunities by holding instruments from different markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance